Applied Therapeutics announced FDA acceptance and priority review of new drug application for Govorestat for the treatment of classic galactosemia. Govorestat is a central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG.
Search 
+86 21 5895 0110 
![methyl 4-[3-(tert-butoxy)-3-oxopropanoyl]thiophene-3-carboxylate](https://images.chemenu.com/attachments/products_new/svg/2170729-43-6.svg)
![tert-butyl 2-{4-oxo-3H,4H-thieno[3,4-d]pyridazin-1-yl}acetate](https://images.chemenu.com/attachments/products_new/svg/2170729-41-4.svg)
